undamentalytics Newsletter
Sign in

Insight Molecular Diagnostics Inc. key statistics and ratios

In fiscal 2025, Insight Molecular Diagnostics Inc. had a net margin of -1238.5%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin—<−999%<−999%<−999%<−999%<−999%<−999%<−999%
Return on equity−83.9%−136.4%−129.9%−146.5%−101.5%———
Return on assets−68.6%−87.8%−59.6%−56.2%−31.8%−110.3%−165.1%−178.8%
R&D as % of revenue—805.9%229.1%762.1%618.4%523.1%392.1%>999%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 2 checks passed · June 30, 2026
What it owns · $29m
Short-term assets $21mLonger-term assets $9m
What it owes, and who funded it · $51m
Short-term liabilities $10mLonger-term liabilities $40mShareholders' equity $-21m
  • Short-term assets cover short-term liabilities $21m of assets due within a year against $10m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $21m short-term assets against $40m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Insight Molecular Diagnostics Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

20 /100

Weak moat

How hard Insight Molecular Diagnostics's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -20.7% of total assets over 6 years.

  • Pricing power 6 / 20

    Gross margin has been a median 39.6%, moving by 20.1 percentage points (standard deviation) across 5 years.

  • Durability 10 / 20

    Operating margin has been a median -2255.1%; its worst year was -5126.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -1856.2% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ICU vs IMDXFEMY vs IMDXIMDX vs PLSE

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Insight Molecular Diagnostics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Insight Molecular Diagnostics Inc.